Project Grant HT94252510722
Award Date
7/1/25
Completion Date
6/30/29
Dollars Obligated
$4.7M
Federal Agency
Defense Health Agency
Awardee
Hbvtech, L.l.c (WEXNYHY4EZB5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Germantown, MD, USA
Similar Awards
Hbvtech received a $279,854 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will support Hbvtech's research from May 2021 through April 2023 to develop a novel hepatitis B virus drug aimed at effectively curing chronic hepatitis B. The Military Medical Research and Development program seeks to transform military and public health through innovative medical research solutions,...
The Department of the Army Medical Command awarded a $5.5 million Project Grant to Carogen Corporation to support the Combination of HBV Immunotherapy with shRNA-Mediated PD-1/PDL Checkpoint Inhibition for Treatment of Chronic HBV from September 15, 2022 through September 14, 2025. This funding supports research under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research and develop...
The Department of the Army Medical Command awarded Invvax, Inc. a $1,878,970 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research titled "Invariance Mapping of the Complete HBV Genome and Testing of MRE11 Repair Nuclease Toward the Improvement of CRISPR/Cas Therapy for Hepatitis B." The period of performance is from September 1, 2022 to August 31, 2026. Under this award, Invvax will conduct research to map the complete genome of...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $629,992.00 to Carogen Corp to test the safety and efficacy of CARG-201, an RNA replicon-based therapeutic vaccine for the treatment of chronic hepatitis B virus. The award period runs from September 1, 2024 to August 31, 2025. Carogen Corp, a minority-owned and small disadvantaged biopharmaceutical business, specializes in developing innovative...
This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
The Project Grant award R01AI179309 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding a 5-year, $762,072 translational research project to discover a safe and effective long-acting antiviral therapy for hepatitis B (HBV). The research aims to leverage expertise and collaboration to transform existing short-acting oral antiviral drugs into a new long-acting injectable HBV therapy. Key goals...
The federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,480,488 to Brigham & Women's Hospital Inc. to research the combination of mRNA nanotherapy with standard antiangiogenic/immunotherapy for hepatocellular carcinoma (HCC). The research project runs from September 1, 2023 to August 31, 2026. As part of this effort, Massachusetts General Hospital will conduct preclinical studies to evaluate the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $598,764 to The Trustees of Princeton University to conduct research aimed at disrupting the formation of HBV cccDNA to combat chronic HBV infection, particularly in the context of HIV co-infection. The key objectives are to: 1) determine whether genetic disruption of host factors involved in HBV cccDNA...
This federal Project Grant award from the Defense Health Agency supports Albany Medical College's research project titled "TARGETING DENDRITIC CELLS TO PREVENT HBV CHRONIC DISEASE". The $2,464,874 award, which runs from July 1, 2024 to June 30, 2028, is funded through the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420). The project aims to advance medical knowledge and improve healthcare for military service members, veterans, and their...